SCHEMBL4432537

SCHEMBL4432537

CC(C)CCC[C@@H](C)[C@H]1CCC2C3CC=C4CC(OC(=O)c5ccc([N+](=O)[O-])cc5)CC[C@]4(C)C3CC[C@@]21C

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLA1 P09884 1/20 0.68
CYP46A1 Q9Y6A2 2/20 0.66
OSBP P22059 3/20 0.62
USP2 O75604 2/20 0.62
RORC P51449 2/20 0.62
LMNA P02545 1/20 0.62
ABCB1 P08183 1/20 0.62
OSBP2 Q969R2 1/20 0.62
NPC1L1 Q9UHC9 2/20 0.57
NR1H3 Q13133 4/20 0.56
NPC1 O15118 1/20 0.55
GBA1 P04062 2/20 0.54
UGCG Q16739 2/20 0.54
GBA2 Q9HCG7 2/20 0.54
CYP1A2 P05177 1/20 0.54
GRIN1 Q05586 1/20 0.53
GRIN2A Q12879 1/20 0.53
PLA2G2A P14555 1/20 0.52
EPHA2 P29317 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12695616 1.00 POLA1 (0.68) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL5888471 1.00 POLA1 (0.68) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL14674808 0.92 POLA1 (0.68) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL4419192 0.92 POLA1 (0.68) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL14684819 0.92 POLA1 (0.68) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL4419195 0.92 POLA1 (0.68) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL28361659 0.92 POLA1 (0.68) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL18904679 0.92 POLA1 (0.70) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL14138204 0.92 POLA1 (0.70) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL11288161 0.92 POLA1 (0.70) POLA1CYP46A1OSBPUSP2RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9204807-B2 Devices for non-contact thermographic mapping of tissue for viability assessment and methods of their use EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2015-12-08 US claimed
US-20140236020-A1 DEVICES FOR NON-CONTACT THERMOGRAPHIC MAPPING OF TISSUE FOR VIABILITY ASSESSMENT AND METHODS OF THEIR USE EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2014-08-21 US claimed
US-20080181928-A1 COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY MIV THERAPEUTICS, INC. (CA) 2008-07-31 US claimed
US-11918770-B2 Implants for localized drug delivery and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-05 US disclosed
US-20220184362-A1 Implants for Localized Drug Delivery and Methods of Use Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-06-16 US disclosed
US-11324935-B2 Implants for localized drug delivery and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-05-10 US disclosed
US-10912933-B2 Implants for localized drug delivery and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-02-09 US disclosed
EP-3183026-B1 IMPLANTS FOR LOCALIZED DRUG DELIVERY AND METHODS OF USE THEREOF UNIV CALIFORNIA (US) 2019-10-30 EP disclosed
US-20190184145-A1 Implants for Localized Drug Delivery and Methods of Use Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-06-20 US disclosed
US-20170224970-A1 Implants for Localized Drug Delivery and Methods of Use Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-08-10 US disclosed
EP-3183026-A1 IMPLANTS FOR LOCALIZED DRUG DELIVERY AND METHODS OF USE THEREOF The Regents of The University of California (US) 2017-06-28 EP disclosed
WO-2008077248-A1 COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY MIV THERAPEUTICS INC. (CA) 2008-07-03 WO disclosed
WO-2008077247-A1 COATINGS FOR IMPLANTABLE MEDICAL DEVICES COMPRISING CHOLESTEROL MIV THERAPEUTICS INC. (CA) 2008-07-03 WO disclosed
US-7022331-B2 Thermochromic/photochromic cosmetic compositions Theisen, Lyle (US) 2006-04-04 US disclosed
US-20020192247-A1 Thermochromic/photochromic cosmetic compositions THEISEN LYLE (US) 2002-12-19 US disclosed
US-4999348-A Sustained Release and Enhanced Penetration of Vitamin A ESTEE LAUDER INC. (US) 1991-03-12 US disclosed
US-4966205-A Method and apparatus for charging transparent material POLA CHEMICAL INDUSTRIES LTD. (JP) 1990-10-30 US disclosed
US-4597942-A LIQUID CRYSTALS GRAPHIC CONTROLS CANADA LTD. (CA) 1986-07-01 US disclosed
US-4383738-A PLEOCHROIC DYE, OPTICALLY ACTIVE DOPANT SHARP KABUSHIKI KAISHA (JP) 1983-05-17 US disclosed
US-4060910-A Orientation system GELL JR HAROLD A 1977-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080181928-A1 COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY LIPA, SGMS2, SGMS1 POLA1 4883/4885CYP46A1 357/4885OSBP 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.